Our advantages and services that will satisfy you:
News
December 21, 2018, The U.S. Food and Drug Administration today approved Ultomiris (ravulizumab) injection for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease.
“The approval of Ultomiris will change the way that patients with PNH are treated,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and…
December 21, 2018, The U.S. Food and Drug Administration today approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients, two years of age and older.
“Prior to today’s approval, there had been no FDA approved therapies for BPDCN. The standard of care has been intensive chemotherapy followed by bone m…
Asparlas is an asparagine specific enzyme.
Asparlas is specifically indicated as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age 1 month to 21 years.
Asparlas is supplied as an injection for intravenous administration. The recommended dosage is 2,500 units/m2 intravenously no more frequently than every 21 day…
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties.[A37348] The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies.[A40254] Prucalopride was developed by Shire…
November 28, 2018, The U.S. Food and Drug Administration today approved Xospata (gilteritinib) tablets for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. The FDA also approved an expanded indication for a companion diagnostic, to include use with Xospata. The LeukoStrat CDx FLT3 Mutation Assay,…
November 28, 2018,
The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare autoimmune disorder that affects the connection between nerves and muscles and causes weakness and other symptoms in affected patients. This is the first FDA approval of a treatment for LEMS.
“There has b…
November 26, 2018, The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker).
This is the second time the agency has approved a cancer treatment based on a common biomarker across different types of tumors rather than the location in the body where the…
November 21, 2018, The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intens…
November 20, 2018,
The U.S. Food and Drug Administration today approved Gamifant (emapalumab-lzsg) for the treatment of pediatric (newborn and above) and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) who have refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. This FDA approval is the first for a drug specifically for HLH.
"Primary H…
November 16, 2018, The U.S. Food and Drug Administration today approved Aemcolo (rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers’ diarrhea caused by noninvasive strains of Escherichia coli (E. coli), not complicated by fever or blood in the stool.
"Travelers' diarrhea affects millions of people each year and having treatment options for this conditio…
On November 9, 2018, the FDA approved the new drug Yupelri (Revefenacin) for the treatment of patients with moderate to very severe chronic obstructive pulmonary disease.
Yupelri (Revefenacin) is a nebulizer for long-acting muscarinic antagonists (LAMA). It has a high lung specificity and maintains long-lasting bronchiectasis with only one use per day while preventing systemic side effects of mus…
On November 2, 2018, the US Food and Drug Administration approved lorlatinib (Lorbrena) to accelerate the approval of patients for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC), which have been used in one or more types of ALK cheese. Progression on tyrosine kinase inhibitors (TKIs).
Specifically, lolatinib is approved for the treatment of metastatic disease with xalk…